ProCE Banner Activity

Optimizing JAK Inhibitor Therapy in Myelofibrosis: Personalizing the Path Forward for Every Patient

Clinical Thought

During a recent live discussion series, I was frequently asked how I approach initial and subsequent JAK inhibitor therapy in myelofibrosis management. In this commentary, I walk through my approach based on both available clinical data and real-world evidence. 

Released: April 11, 2025

Expiration: October 10, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from CTI BioPharma Corp., a Sobi Company; and Incyte Corporation.

CTI BioPharma Corp., a Sobi Company

Incyte Corporation

Disclosure

Primary Author

Pankit Vachhani, MD: consultant/advisor/speaker: AbbVie, Amgen, Blueprint Medicines, Cogent Biosciences, Disc Medicine, Genentech, Geron, GlaxoSmithKline, Incyte, Karyopharm, Merck, MorphoSys, Novartis, Pfizer, Servier, Sobi, Stemline, Takeda.